ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
Background: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%. Materials and Methods: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| coleção: | Lung India |
| Assuntos: | |
| Acesso em linha: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2017;volume=34;issue=5;spage=411;epage=414;aulast=Suryavanshi |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|